Company Mission
Integrative Health Technologies, Inc’s (IHTI) mission is use its scientific and testing resources, research and development experience, and financial resources to aid healthcare companies in the discovery, testing and marketing of their healthcare products and technologies. In return for this support, IHTI receives equity or stock in the companies for whom it provided these services or royalties from the products and technologies it helped develop.
The Company is limiting its involvement to healthcare entities that can provide products and services that can contribute to the prevention and reduction of the global health problems as reported by the World Health Organization (WHO):
“Nearly 400 million people will die from heart disease, diabetes and other chronic ailments over the next 10 years, but that many of those deaths can be prevented by healthier lifestyles, diets and increased physical activity. Exercise and better diets can help prevent 80 percent of premature cases of heart disease, strokes and diabetes… The financial burden from an increasing death toll from such non-communicable diseases will also be enormous. China could spend $558 billion, Russia, $303 billion and India, $236 billion over the next decade treating heart disease, strokes and diabetes. ‘The lives of far too many people in the world are being blighted and cut short by chronic diseases, diseases that can be prevented with healthier diets and increased physical activity" said Lee Jong-Wook, WHO Director-General.”
IHTI’s, business plan has been is to conduct research and development of products, programs and technologies that can enhance “body composition”, decreasing body fat while maintaining or increasing lean mass and bone density. Improvements in these parameters will make major contribution to the reduction of risk factors for three major global disorders: osteoporosis, obesity and “sarcopenia” (the progressive loss of lean mass with aging and inactivity). All three of these disorders result from sub-optimal levels of muscle, fat and bone mass, or a combination of the three--osteoporosis is the result of too little bone mass or density; obesity is the result of too much fat mass; sarcopenia is the result of too little muscle mass. Click on the following buttons for more information on the Company’s progress to date and its potential for future growth.
Scientific Advisory Board lists the current members and institutional affiliations of Board members whom the Company relies upon for their independent evaluation of its research and development.
Strategic Alliances lists and describes the describes the organizations with whom the Company has formed strategic alliances or research and development relationships.
Body Composition Biomarkers provides information on the importance of using changes in ‘Body Composition’, instead of scale weight, to evaluate the safety and efficacy of medical and nutritional interventions, the research conducted to date, and current and future R & D activities measuring changes in body composition parameters.
On-site DEXA and Blood Testing provides information on why Dual Energy X-ray Absorptiometry (DEXA) is considered the “gold standard” for measuring fat, lean and bone and the Company’s mobile testing units that has enabled it to provide testing throughout the United States and Canada.
On-going R & D describes the Company’s on-going clinical trials and research and the development of health-enhancing and risk reducing products and technologies.
The 2-Million Tests Database is the result of accumulating a nation sample of over 2 million sophisticated medical measurements, including over 22,000 DEXA tests, spanning over the last 30 years.
